TMCnet News

Research and Markets: Global Febrile Neutropenia Therapeutics Pipeline Review 2014 - Analysis of 11 Companies & 12 Drug Profiles
[April 23, 2014]

Research and Markets: Global Febrile Neutropenia Therapeutics Pipeline Review 2014 - Analysis of 11 Companies & 12 Drug Profiles


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/d8cp8p/febrile) has announced the addition of the "Febrile Neutropenia - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Febrile Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Febrile Neutropenia and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

    The report provides a snapshot of the global therapeutic landscape of Febrile Neutropenia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Febrile Neutropenia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Febrile Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Febrile Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products



Companies Involved in Therapeutics Development

  • Hospira, Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Biocon Limited
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • Taiho Pharmaceutical Co., Ltd.
  • Sandoz Inc.
  • Xenetic Biosciences plc
  • USV Limited
  • Aequus BioPharma, Inc.

Drug Profiles


  • pegfilgrastim
  • vancomycin hydrochoride
  • (piperacillin sodium + tazobactam sodium)
  • filgrastim biosimilar
  • pegfilgrastim biosimilar
  • pegfilgrastim
  • filgrastim
  • pegfilgrastim biosimilar
  • pegfilgrastim biosimilar
  • Stimuxen
  • filgrastim biosimilar
  • pegfilgrastim biosimilar

For more information visit http://www.researchandmarkets.com/research/d8cp8p/febrile


[ Back To TMCnet.com's Homepage ]